Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Early Phase 1

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07677878Phase 1Recruiting

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

Role: lead

NCT07575971Phase 1Recruiting

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

Role: lead

NCT07651475Phase 2Active Not Recruiting

Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Role: lead

NCT07575919Phase 1Recruiting

Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

Role: lead

NCT07587840Phase 2Recruiting

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Role: lead

NCT07586709Early Phase 1Not Yet Recruiting

In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

Role: lead

All 6 trials loaded